D Girard - Concepedia

Author

D Girard

Pfizer (United States)

Also Known As

D GIRARD, D Girard, D. D. Girard, D. Girard, DENNIS GIRARD, Dennis Girard, J L Tellier

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Wisconsin–Green Bay

About

D Girard is an author at Pfizer (United States) specializing in medicine, pharmacology, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	844
2	Health Sciences	7	7	643
3	Arts	1	1	30
4	Business	1	1	30
5	Management	1	1	30

D Girard

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution Agnès Girard, D Girard, A. R. English, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntimicrobial ChemotherapyNew MacrolideAnimal Infection Models	1987	321
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides. G. Michael Bright, A. Nagel, Jon Bordner, The Journal of Antibiotics	1988	237
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro Thomas D. Gootz, Richard P. Zaniewski, S L Haskell, Antimicrobial Agents and Chemotherapy S. PneumoniaeAntimicrobial ChemotherapyAntibiotic ResistanceNew Fluoroquinolone TrovafloxacinCiprofloxacin Mics	1996	134
Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo James A. Retsema, Agnès Girard, D Girard, Journal of Antimicrobial Chemotherapy Antimicrobial SusceptibilityHealth SciencesAntibioticsPneumoniae PopulationLung Infection Model	1990	74
Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection Agnès Girard, D Girard, James A. Retsema Journal of Antimicrobial Chemotherapy	1990	72
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis Agnès Girard, D Girard, Thomas D. Gootz, Antimicrobial Agents and Chemotherapy	1995	72
Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models D Girard, Steven M. Finegan, Michael W. Dunne, Journal of Antimicrobial Chemotherapy	2005	69
Preferential concentration of azithromycin in an infected mouse thigh model James A. Retsema, Jay Bergeron, D Girard, Journal of Antimicrobial Chemotherapy	1993	63
Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections Thomas V. Magee, Sharon L. Ripp, Bryan Li, Journal of Medicinal Chemistry Health SciencesAntibioticsMedicineKlebsiella PneumoniaeMacrolides Addresses Resistance	2009	54
Effect of early postnatal exposure to polychlorinated biphenyls (PCBs) on fertility in male rats D. B. Sager, W. Shih-Schroeder, D Girard Bulletin of Environmental Contamination and Toxicology Endocrine DisruptorsInfertilityAndrologyFertilityMedicine	1987	50

Page 1